Status:
RECRUITING
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Prostate Cancer
Eligibility:
MALE
40-80 years
Phase:
PHASE2
Brief Summary
This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostat...
Eligibility Criteria
Inclusion
- Age greater than 40 and less than 80 years
- Clinical suspicion or history of prostate cancer reflected by one of the following:
- PSA \> 4ng/ml
- Abnormal DRE exam
- Known tissue diagnosis of prostate cancer from prior workup
- Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment
Exclusion
- Inability to undergo MRI scan
- Inability to receive IV contrast as per institutional protocol.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04698564
Start Date
December 1 2020
End Date
December 31 2027
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201